Stefania Butini

List of Publications by Year in Descending Order

136 papers	3,253 citations	33 h-index	46 g-index
150 ext. papers	3,785 ext. citations	5.4 avg, IF	4.69 L-index

#	Paper	IF	Citations
136	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.. *European Journal of Medicinal Chemistry*, **2022**, 235, 114274	6.8	0
135	In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). *Computation*, **2022**, 10, 69	2.2	
134	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.. *European Journal of Medicinal Chemistry*, **2022**, 238, 114409	6.8	0
133	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E□TCL1 mice through the JNK/STAT4/p66Shc axis. *Pharmacological Research*, **2021**, 174, 105965	10.2	
132	Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents. *ACS Chemical Neuroscience*, **2021**, 12, 1716-1736	5.7	3
131	Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity. *European Journal of Medicinal Chemistry*, **2021**, 215, 113227	6.8	2
130	A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds. *Scientific Reports*, **2021**, 11, 14069	4.9	0
129	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 9960-9988	8.3	5
128	Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. *European Journal of Medicinal Chemistry*, **2021**, 212, 112998	6.8	7
127	Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions. *ACS Chemical Neuroscience*, **2020**, 11, 1791-1800	5.7	5
126	Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development. *ACS Chemical Neuroscience*, **2020**, 11, 2173-2191	5.7	5
125	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. *Current Topics in Medicinal Chemistry*, **2020**, 20, 433-457	3	17
124	Screening and Phenotypical Characterization of Histone Deacetylase 8 (HDAC8) Inhibitors as Multistage Antischistosomal Agents. *ACS Infectious Diseases*, **2020**, 6, 100-113	5.5	11
123	Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. *Medicinal Research Reviews*, **2020**, 40, 1002-1060	14.4	21
122	Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2268-2276	4.3	8
121	Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. *Journal of Medicinal Chemistry*, **2020**, 63, 13466-13513	8.3	28
120	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. *Journal of Medicinal Chemistry*, **2020**, 63, 23-39	8.3	39

119	Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. *European Journal of Medicinal Chemistry*, **2019**, 183, 111674	6.8	7
118	Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders. *ACS Medicinal Chemistry Letters*, **2019**, 10, 228-236	4.3	9
117	Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. *Drug Discovery Today*, **2019**, 24, 1370-1388	8.8	17
116	Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). *Bioorganic Chemistry*, **2019**, 89, 103020	5.1	10
115	A light in the dark: state of the art and perspectives in optogenetics and optopharmacology for restoring vision. *Future Medicinal Chemistry*, **2019**, 11, 463-487	4.1	6
114	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using Structure-Based Combinatorial Library Design Approach. *Frontiers in Chemistry*, **2019**, 7, 574	5	16
113	Dealing with schistosomiasis: Current drug discovery strategies. *Annual Reports in Medicinal Chemistry*, **2019**, 53, 107-138	1.6	7
112	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. *Medicinal Chemistry*, **2019**, 15, 755-770	1.8	16
111	A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. *Molecules*, **2019**, 24,	4.8	21
110	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. *European Journal of Medicinal Chemistry*, **2019**, 162, 290-320	6.8	21
109	Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues. *European Journal of Medicinal Chemistry*, **2018**, 150, 698-718	6.8	17
108	(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation. *Journal of Medicinal Chemistry*, **2018**, 61, 2124-2130	8.3	11
107	Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. *ChemMedChem*, **2018**, 13, 422-430	3.7	31
106	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. *European Journal of Medicinal Chemistry*, **2018**, 157, 127-138	6.8	29
105	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. *ChemMedChem*, **2018**, 13, 2090-2103	3.7	11
104	iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome. *Experimental Cell Research*, **2018**, 368, 225-235	4.2	31
103	A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents. *Tetrahedron Letters*, **2018**, 59, 4466-4470	2	3
102	Synthetic studies toward bicyclic endoperoxides presenting polar side chains. *Tetrahedron Letters*, **2018**, 59, 4330-4333	2	1

101	Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors. *ACS Chemical Biology*, **2018**, 13, 2406-2413	4.9	17
100	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer□s disease. *Progress in Neurobiology*, **2017**, 151, 4-34	10.9	94
99	Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX. *European Journal of Medicinal Chemistry*, **2017**, 135, 479-490	6.8	24
98	First dual AK/GSK-3□inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. *European Journal of Medicinal Chemistry*, **2017**, 138, 438-457	6.8	24
97	The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. *Scientific Reports*, **2017**, 7, 11152	4.9	27
96	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. *ChemMedChem*, **2017**, 12, 2074-2085	3.7	8
95	Identification of novel fluorescent probes preventing PrP replication in prion diseases. *European Journal of Medicinal Chemistry*, **2017**, 127, 859-873	6.8	33
94	Computational Tool for Fast Evaluation of ERG K Channel Affinity. *Frontiers in Chemistry*, **2017**, 5, 7	5	38
93	Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. *Cancer Biology and Therapy*, **2016**, 17, 849-58	4.6	15
92	Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats. *Neuropsychopharmacology*, **2016**, 41, 1329-39	8.7	27
91	Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. *European Journal of Medicinal Chemistry*, **2016**, 121, 864-879	6.8	65
90	Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. *Future Medicinal Chemistry*, **2016**, 8, 1573-87	4.1	15
89	The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. *International Journal of Oncology*, **2016**, 49, 74-88	4.4	21
88	Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells. *Investigational New Drugs*, **2016**, 34, 663-76	4.3	6
87	In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. *Journal of Molecular Graphics and Modelling*, **2016**, 64, 121-130	2.8	15
86	Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs. *Tetrahedron Letters*, **2016**, 57, 920-923	2	3
85	Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors. *Chemical Biology and Drug Design*, **2016**, 87, 112-20	2.9	5
84	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. *Journal of Medicinal Chemistry*, **2016**, 59, 2612-32	8.3	49

83	The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. *Investigational New Drugs*, **2016**, 34, 159-67	4.3	4
82	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. *RSC Advances*, **2016**, 6, 64651-64664	3.7	16
81	Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines. *Journal of Cancer*, **2016**, 7, 2367-2377	4.5	10
80	Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. *Frontiers in Neuroscience*, **2016**, 10, 201	5.1	32
79	Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. *Frontiers in Neuroscience*, **2016**, 10, 451	5.1	43
78	Development of novel cyclic peptides as pro-apoptotic agents. *European Journal of Medicinal Chemistry*, **2016**, 117, 301-20	6.8	16
77	Polypharmacology of dopamine receptor ligands. *Progress in Neurobiology*, **2016**, 142, 68-103	10.9	38
76	Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2016**, 31, 98-109	5.6	16
75	Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. *RSC Advances*, **2015**, 5, 22431-22448	3.7	14
74	Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking. *Scientific Reports*, **2015**, 5, 9705	4.9	40
73	Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents. *European Journal of Medicinal Chemistry*, **2015**, 102, 648-60	6.8	7
72	Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5412-8	2.9	12
71	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. *MedChemComm*, **2015**, 6, 357-362	5	35
70	Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines. *Molecular Medicine Reports*, **2015**, 12, 3748-3754	2.9	7
69	Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2015**, 15, 648-58	3.2	12
68	From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. *RSC Advances*, **2014**, 4, 4769-4781	3.7	12
67	Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. *Journal of Medicinal Chemistry*, **2014**, 57, 9578-97	8.3	38
66	Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation. *CNS Neuroscience and Therapeutics*, **2014**, 20, 624-32	6.8	41

65	The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells. *Biochemical Pharmacology*, **2014**, 87, 611-24	6	17
64	Rational design of the first difluorostatone-based PfSUB1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3582-6	2.9	30
63	HCV-targeted antivirals: current status and future challenges. *Current Pharmaceutical Design*, **2014**, 20, 3445-64	3.3	7
62	A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues. *Tetrahedron Letters*, **2013**, 54, 5387-5390	2	9
61	Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1178-82	4.3	32
60	A stereoselective approach to peptidomimetic BACE1 inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 70, 233-47	6.8	16
59	PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines. *European Journal of Pharmacology*, **2013**, 714, 379-87	5.3	1
58	Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 85-9	2.9	14
57	A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides. *Tetrahedron Letters*, **2013**, 54, 1233-1235	2	9
56	Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 492-5	2.9	12
55	Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds. *European Journal of Medicinal Chemistry*, **2013**, 63, 85-94	6.8	21
54	The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1787-807	3	33
53	Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents. *Journal of Medicinal Chemistry*, **2012**, 55, 10387-404	8.3	53
52	A straightforward approach for engineering efficacy and selectivity at GPCRs. *Journal of Medicinal Chemistry*, **2012**, 55, 6687-8	8.3	1
51	Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5317-21	2.9	22
50	Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases. *Journal of Medicinal Chemistry*, **2012**, 55, 6898-915	8.3	22
49	Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling. *Journal of Medicinal Chemistry*, **2012**, 55, 6948-67	8.3	34
48	Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies. *Journal of Medicinal Chemistry*, **2011**, 54, 1401-20	8.3	24

47	Selective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1H,3H)-dione: synthesis, molecular modeling, and pharmacological and biostructural characterization. *Journal of Medicinal Chemistry*, **2011**, 54, 4793-805	8.3	17
46	Synthesis and antiplasmodial activity of bicyclic dioxanes as simplified dihydroplakortin analogues. *Journal of Medicinal Chemistry*, **2011**, 54, 5949-53	8.3	24
45	PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. *British Journal of Cancer*, **2011**, 104, 281-9	8.7	25
44	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. *Organic and Biomolecular Chemistry*, **2011**, 9, 5137-48	3.9	40
43	Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2776-9	2.9	13
42	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3935-8	2.9	4
41	The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functional. *Journal of Biological Chemistry*, **2011**, 286, 38383-38389	5.4	11
40	The interactions of the 5-HT3 receptor with quipazine-like arylpiperazine ligands: the journey track at the end of the first decade of the third millennium. *Current Topics in Medicinal Chemistry*, **2010**, 10, 504-26	3	15
39	Malaria chemotherapy: recent advances in drug development. *Recent Patents on Anti-infective Drug Discovery*, **2010**, 5, 195-225	1.6	10
38	Synthesis of dihydroplakortin, 6-epi-dihydroplakortin, and their C10-desethyl analogues. *Journal of Organic Chemistry*, **2010**, 75, 2333-40	4.2	39
37	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. *Journal of Medicinal Chemistry*, **2010**, 53, 4803-7	8.3	22
36	The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. *Biochemical Pharmacology*, **2009**, 77, 310-21	6	9
35	Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials. *Tetrahedron Letters*, **2009**, 50, 5719-5722	2	23
34	Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6063-72	3.4	46
33	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. *Journal of Medicinal Chemistry*, **2009**, 52, 151-69	8.3	71
32	The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. *Cancer Research*, **2009**, 69, 8366-75	10.1	26
31	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization. *Journal of Medicinal Chemistry*, **2009**, 52, 6946-50	8.3	33
30	Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. *Journal of Medicinal Chemistry*, **2009**, 52, 502-13	8.3	50

29	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations. *Journal of Medicinal Chemistry*, **2009**, 52, 1224-8	8.3	15
28	Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. *Journal of Medicinal Chemistry*, **2009**, 52, 3548-62	8.3	32
27	Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. *Biochemical Pharmacology*, **2008**, 76, 156-68	6	6
26	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. *Journal of Medicinal Chemistry*, **2008**, 51, 3154-70	8.3	49
25	An efficient approach to chiral C8/C9-piperazino-substituted 1,4-benzodiazepin-2-ones as peptidomimetic scaffolds. *Journal of Organic Chemistry*, **2008**, 73, 8458-68	4.2	23
24	Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. *Journal of Medicinal Chemistry*, **2008**, 51, 1333-43	8.3	64
23	1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators. *Journal of Medicinal Chemistry*, **2008**, 51, 6614-8	8.3	19
22	Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. *Journal of Medicinal Chemistry*, **2008**, 51, 1278-94	8.3	39
21	A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. *Journal of Molecular Medicine*, **2008**, 86, 457-69	5.5	33
20	Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives. *Tetrahedron Letters*, **2008**, 49, 2074-2077	2	17
19	Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5213-6	2.9	24
18	Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3535-9	2.9	18
17	Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore. *Journal of Medicinal Chemistry*, **2007**, 50, 595-8	8.3	34
16	Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5384-8	2.9	121
15	Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. *Journal of Medicinal Chemistry*, **2006**, 49, 3421-5	8.3	44
14	Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. *Journal of Medicinal Chemistry*, **2005**, 48, 1705-8	8.3	33
13	Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target. *Journal of Medicinal Chemistry*, **2005**, 48, 4367-77	8.3	50
12	Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. *Biochemistry*, **2005**, 44, 9637-44	3.2	62

11	Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 1919-29	8.3	62
10	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. *Journal of Medicinal Chemistry*, **2005**, 48, 7153-65	8.3	41
9	Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. *Journal of Medicinal Chemistry*, **2004**, 47, 143-57	8.3	53
8	Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 425-448	6.8	4
7	Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. *Current Pharmaceutical Design*, **2003**, 9, 599-625	3.3	46
6	A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring. *Tetrahedron*, **2003**, 59, 87-93	2.4	12
5	Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. *Journal of Medicinal Chemistry*, **2003**, 46, 3822-39	8.3	88
4	Polycondensed Heterocycles. Part 12. An Approach to the Synthesis of 2-Acetyl-1?-methyl-1,2,3,4-tetrahydrospiro [isoquinoline-1,4?-pyrrolidine]-2?-one.. *ChemInform*, **2002**, 33, 154-154		
3	Polycondensed heterocycles. Part 12: An approach to the synthesis of 2-acetyl-1?-methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4?-pyrrolidine]-2?-one. *Tetrahedron*, **2002**, 58, 3689-3692	2.4	7
2	Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. *Journal of Medicinal Chemistry*, **2002**, 45, 344-59	8.3	32
1	Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies. *Journal of Medicinal Chemistry*, **1999**, 42, 4362-79	8.3	91